Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Laboratory Medicine and Nosocomial Infections: Surveying HIAs

By LabMedica International staff writers
Posted on 22 Feb 2010
Seventh article in Laboratory Medicine and Nosocomial Infections series - In January 2009, the US Department of Health and Human Services (Washington DC, USA) established a set of five-year national prevention targets to reduce and possibly eliminate healthcare-associated infections (HIAs). More...
Two consortiums were formed in 2008 to establish connections between hospital labs and leading academic labs to track drug-resistant patterns and new multiple antibiotic-resistant strains.

The results of one International Nosocomial Infection Control Consortium (INICC) surveillance study from 2002 through 2007 in 98 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe were reported in the November 2008 American Journal of Infection Control (AJIC) by Victor D. Rosenthal, M.D., M.Sc., CIC, International Nosocomial Infection Control Consortium (INICC; Buenos Aires, Argentina).

Prospective data from 43,114 patients hospitalized in the Consortium's hospital ICUs for an aggregate of 272,279 days were collected. The pooled rate of central line-associated bloodstream infections (CLABs) in the INICC ICUs was nearly 3-fold higher than reported from comparable U.S. ICUs and the overall rate of ventilator-associated pneumonia was far higher, as was the rate of catheter-associated urinary tract infection. The frequencies of resistance of Staphylococcus aureus isolates to methicillin (MRSA), Enterobacter species to ceftriaxone, and Pseudomonas aeruginosa to fluoroquinolones were also far higher in the consortium's ICUs, and the crude unadjusted excess mortalities of device-related infections ranged from 14.3% to 27.5% (ventilator-associated pneumonia).

Related Links:
US Department of Health and Human Services
International Nosocomial Infection Control Consortium


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.